In light of the COVID-19 crisis, LYPHE Group has secured an emergency planning agreement with the Home Office and the Office of Medicinal Cannabis in the Netherlands to allow for the first time ever the export of sublingual medical cannabis oil tinctures for patients into the UK.
During such challenging times it is deemed absolutely right that policies change on certain life or death situations whilst protecting the liberty of the nation. The UK is rushing in new laws over the coming days which shall ease the burden on frontline staff and increase the NHS workforce, whilst containing, managing, supporting, and protecting the population from COVID-19. However, LYPHE Group are working to ensure medical cannabis patients do not get left behind.
It might feel that during such unrest, with fear and panic widespread and an undefined end point to the crisis, patients that rely on the medicinal benefits of medical cannabis are not as important. This could not be further from reality. Now, more than ever, it is critical that seriously unwell patients that suffer from epilepsy, anxiety, chronic pain, and other chronic diseases receive the medicines they need to avoid adding more pressure to the NHS.
LYPHE Group secures COVID-19 agreement
As part of LYPHE Group’s COVID-19 emergency planning, an agreement has been made with the Home Office and the Office of Medicinal Cannabis in the Netherlands to allow for the first time ever the export of sublingual medical cannabis oil tinctures into the UK.
The change of policy is a temporary measure to enable patients that have been using the oils made from Dutch based manufacturer Bedrocan’s product, to continue to receive their medicine. This necessary move has been as a consequence of the shutting of borders and cancellation of transport links.
Up until now LYPHE Group Chief Pharmacist, Chris Ashton, has been making trips to the Netherlands almost weekly in order to fulfil prescriptions for patients based on oil that has not been permitted to be exported from The Hague.
Chris Ashton said of the policy change: “For months we have been going out of our way to obtain these medicines for extremely unwell patients. This oil changes lives. We are proud to have led the negotiations with the Home Office and Office of Medicinal Cannabis, and the result will mean that the dozens of nervous patients concerned that they will not be able to continue on their treatment plans can rest assured.
“A huge burden lifted in amongst the coronavirus pandemic.”
Patients are being advised to contact Dispensary Green for more information on receiving their medical cannabis treatments: email@example.com.